Uses of anthology

In a review of a book Wielcy artyści ucieczek. Antologia tekstów o "Życiu i czasach Michaela K." w trzydziestą rocznicę publikacji, an author analyses the mere idea of an anthology of interpretations, describing its two possible understandings: as a collection of incomparable perspectives and as a field of conflict. The author emphasizes difficulties of interpretational procedures related to the novel by J.M. Coetzee and points to a political meanings of an act of reading. Additionally, texts collected in the anthology are classified by different attitudes towards the work of meanings in the novel, and some reductional practices are criticized. Finally, the author places the anthology in a wider horizon of interpretational strategies in contemporary humanities, asking questions regarding their importance - or lack of it

Niebezpieczeństwa zbawienia (Adama Lipszyca Sprawiedliwość na końcu języka. Czytanie Waltera Benjamina)

Dangers of salvation This review of Sprawiedliwość na końcu języka. Czytanie Waltera Benjamina by Adam Lipszyc locates the book in the framework of a wider phenomenon of interest in Walter Benjamin’s writings in contemporary Polish humanities. Author of the review indicates the basic assumption of homogeneity of the Benjamin’s writings, involving continuous elaboration of the “justice act” formula. The resulting preference for theological perspective, which becomes axiological frame for the analysis contained in the book, is questionable to reviewer. Despite these methodological concerns, the review underlines the impressive character of the analyzes conducted by Lipszyc, including not only a detailed reconstruction of Benjamin’s thought, but also the broader context of the philosophy of the twentieth century. The most important idea for literary studies turns out to be a dialectical relationship between philosophy and literature (criticism, history, translatology), which is being introduced by Lipszyc following Benjamin’s work

Pożytki z antologii (O książce Wielcy artyści uczieczek. Antologia tekstów o “Życiu i czasach Michaela K.” w trzydziestą rocznicę publikacji)

Uses of anthologyIn a review of a book Wielcy artyści ucieczek. Antologia tekstów o „Życiu i czasach Michaela K.” w trzydziestą rocznicę publikacji, an author analyses the mere idea of an anthology of interpretations, describing its two possible understandings: as a collection of incomparable perspectives and as a field of conflict. The author emphasizes difficulties of interpretational procedures related to the novel by J.M. Coetzee and points to a political meanings of an act of reading. Additionally, texts collected in the anthology are classified by different attitudes towards the work of meanings in the novel, and some reductional practices are criticized. Finally, the author places the anthology in a wider horizon of interpretational strategies in contemporary humanities, asking questions regarding their importance – or lack of it

Dangers of salvation

This review of Sprawiedliwość na końcu języka. Czytanie Waltera Benjamina by Adam Lipszyc locates the book in the framework of a wider phenomenon of interest in Walter Benjamin’s writings in contemporary Polish humanities. Author of the review indicates the basic assumption of homogeneity of the Benjamin’s writings, involving continuous elaboration of the “justice act” formula. The resulting preference for theological perspective, which becomes axiological frame for the analysis contained in the book, is questionable to reviewer. Despite these methodological concerns, the review underlines the impressive character of the analyzes conducted by Lipszyc, including not only a detailed reconstruction of Benjamin’s thought, but also the broader context of the philosophy of the twentieth century. The most important idea for literary studies turns out to be a dialectical relationship between philosophy and literature (criticism, history, translatology), which is being introduced by Lipszyc following Benjamin’s work

Proteomics: Challenges, Techniques and Possibilities to Overcome Biological Sample Complexity

Proteomics is the large-scale study of the structure and function of proteins in complex biological sample. Such an approach has the potential value to understand the complex nature of the organism. Current proteomic tools allow large-scale, high-throughput analyses for the detection, identification, and functional investigation of proteome. Advances in protein fractionation and labeling techniques have improved protein identification to include the least abundant proteins. In addition, proteomics has been complemented by the analysis of posttranslational modifications and techniques for the quantitative comparison of different proteomes. However, the major limitation of proteomic investigations remains the complexity of biological structures and physiological processes, rendering the path of exploration paved with various difficulties and pitfalls. The quantity of data that is acquired with new techniques places new challenges on data processing and analysis. This article provides a brief overview of currently available proteomic techniques and their applications, followed by detailed description of advantages and technical challenges. Some solutions to circumvent technical difficulties are proposed

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Key points CarPan is a highly active, steroid-sparing regimen, effective in both bortezomib-sensitive and refractory patients.The safety profile of CarPan, particularly thrombocytopenia and gastrointestinal adverse events, compares favorably with that of panobinostat and bortezomib

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs 51%, P = 0.020). Median overall survival was 5.6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/92443/1/bjh9173.pd

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses

Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively. Splitting the first intravenous infusion of daratumumab over 2 days is an approved alternative dosing regimen to reduce the duration of the first infusion and provide flexibility for patients and healthcare providers. Methods: The feasibility of splitting the first 16-mg/kg infusion into two separate infusions of 8 mg/kg on Days 1 and 2 of the first treatment cycle was investigated in two cohorts [daratumumab, carfilzomib, and dexamethasone (D-Kd) and daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)] of the phase 1b MMY1001 study. Additionally, a population pharmacokinetic (PK) analysis and simulations were used to compare the PK profiles of the split first dose regimen with the recommended single first dose regimens of daratumumab in previously approved indications. Results: In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml]. At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml]. The population PK simulations demonstrated virtually identical PK profiles after the first day of treatment for all approved indications and recommended dosing schedules of daratumumab. Conclusion: These data support the use of an alternative split first dose regimen of intravenous daratumumab for the treatment of MM. Trial Registration: ClinicalTrials.gov number, NCT01998971